AL8326 tablets

DRUG6 trials

Sponsors

Advenchen Laboratories Nanjing Ltd., Advenchen Laboratories, LLC

Conditions

Advanced Solid TumorsDiet, High-FatNon-small Cell Lung CancerPharmacokineticsSmall Cell Lung CancerSmall Cell Lung CarcinomaSolid Tumor

Phase 1

A Phase I Study of AL8326 in Advanced Solid Tumor

Advenchen Laboratories Nanjing Ltd.Advanced Solid Tumors

Start: 2017-08-17End: 2023-12-31Target: 40Updated: 2021-05-18

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

Advenchen Laboratories Nanjing Ltd.Small Cell Lung Cancer

Start: 2020-10-19End: 2021-09-30Target: 237Updated: 2021-05-18

A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects

Advenchen Laboratories Nanjing Ltd.Diet, High-Fat, Pharmacokinetics

Start: 2022-06-21End: 2022-12-31Target: 16Updated: 2022-08-03

A Study of AL8326 in Non-Small Cell Lung Cancer

Active, not recruitingNCT06794957

Advenchen Laboratories, LLCNon-small Cell Lung Cancer

Start: 2022-05-19End: 2027-12-31Target: 158Updated: 2025-01-27

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

RecruitingNCT07392736

Advenchen Laboratories, LLCSolid Tumor

Start: 2021-10-26End: 2029-11-07Target: 228Updated: 2026-02-06

Phase 3

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

RecruitingNCT06247605

Advenchen Laboratories Nanjing Ltd.Small Cell Lung Carcinoma

Start: 2023-10-26End: 2029-07-31Target: 243Updated: 2024-02-08

Related Papers

Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment.

Journal of Clinical Oncology2023-06-011 citations